These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 10961352

  • 21. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P, Vergote I.
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB.
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Antiestrogenic agents for treatment of advanced breast cancers].
    Kimura M.
    Nihon Rinsho; 2000 Apr; 58 Suppl():311-6. PubMed ID: 11026011
    [No Abstract] [Full Text] [Related]

  • 29. Breast cancer prevention by antihormones and other drugs: where do we stand?
    Lazzeroni M, DeCensi A.
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):657-72, vii. PubMed ID: 23915737
    [Abstract] [Full Text] [Related]

  • 30. NICE recommends preventive drugs for breast cancer.
    Wise J.
    BMJ; 2013 Jun 25; 346():f4116. PubMed ID: 23801701
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
    Johnson JA, Hamadeh IS, Langaee TY.
    J Natl Cancer Inst; 2015 Feb 25; 107(2):. PubMed ID: 25638249
    [No Abstract] [Full Text] [Related]

  • 35. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
    Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P, Italian Tamoxifen Study Group.
    J Natl Cancer Inst; 2003 Jan 15; 95(2):160-5. PubMed ID: 12529349
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Primary prevention of breast cancer: new approaches.
    Cummings SR.
    Maturitas; 2007 May 20; 57(1):39-41. PubMed ID: 17391879
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Breast cancer chemoprevention.
    Rosenbaum Smith SM, Osborne MP.
    Am J Surg; 2000 Oct 20; 180(4):249-51. PubMed ID: 11113429
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.